Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor

S Patel, S Patel, R Marwood, F Emms, D Marston, PD Leeson, NR Curtis, JJ Kulagowski and SB Freedman

Department of Biochemistry and Molecular Biology, Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, UK.

We identified a novel azaindole derivative, L-750,667, that has high affinity (Ki = 0.51 nM) and >2000-fold selectivity for D4 dopamine receptors compared with its activity at D2 and D3 dopamine receptors. L- 750,667 had little affinity for rat D1/D5 dopamine receptors, sigma binding sites, or 5-hydroxytryptamine1A or 5-hydroxytryptamine2 receptors. In functional studies, L-750,667 exhibited high affinity antagonist activity at D4 receptors, reversing dopamine (1 microM)- induced inhibition of cAMP accumulation in human embryonic kidney (HEK) cells expressing the human D4 receptor (hD4 HEK) with an EC50 value of 80 nM. The radioiodinated form of L-750,667 bound specifically to the human dopamine D4 receptor expressed in HEK cells and saturation analysis revealed a single high affinity binding site for [125I]L- 750,667 (Kd = 0.16 +/- 0.06 nM). The maximum number of binding sites (Bmax) estimated using [125I]L-750,667 in hD4 HEK cells was 251 +/- 71 fmol/mg, which correlated well with the Bmax value determined using [3H]spiperone (227 +/- 83 fmol/mg) in the same membrane preparations. The pharmacological profile of [125I]L-750,667 binding to hD4 HEK cells was evaluated using known dopamine receptor agonists and antagonists. The rank order of potencies for dopamine receptor agonists was dopamine > quinpirole > 6,7-aminodihydroxytetralin > 5,6-aminodihydroxytetralin. Dopamine receptor antagonists also showed high affinity, with a rank order of haloperidol > chlorpromazine > domperidone > (+)-butaclamol > (-)-sulpiride = (+)-sulpiride > (+)-SCH23390 > (-)-butaclamol. [125I]L- 750,667, bound to D4 receptors in a stereoselective manner with (+)- butaclamol showing higher activity than its respective enantiomer (-)- butaclamol. These results show that [125I]L-750,667 is a novel, highly selective radioligand for dopamine D4 receptors and may be used to investigate the dopamine D4 receptor population in the central nervous system.

Volume 50, Issue 6, pp. 1658-1664, 12/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				K. Azdad, R. Piet, D. A. Poulain, and S. H. R. Oliet Dopamine D4 Receptor-Mediated Presynaptic Inhibition of GABAergic Transmission in the Rat Supraoptic Nucleus J Neurophysiol, August 1, 2003; 90(2): 559 - 565. [Abstract] [Full Text] [PDF]

				C. J. Price and Q. J. Pittman Dopamine D4 Receptor Activation Inhibits Presynaptically Glutamatergic Neurotransmission in the Rat Supraoptic Nucleus J Neurophysiol, September 1, 2001; 86(3): 1149 - 1155. [Abstract] [Full Text] [PDF]

				J. A. Schetz, P. S. Benjamin, and D. R. Sibley Nonconserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor Are Molecular Determinants of D4-Selective Pharmacology Mol. Pharmacol., January 1, 2000; 57(1): 144 - 152. [Abstract] [Full Text]

				M. J. Millan, A. Newman-Tancredi, M. Brocco, A. Gobert, F. Lejeune, V. Audinot, J.-M. Rivet, R. Schreiber, A. Dekeyne, M. Spedding, et al. S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 167 - 186. [Abstract] [Full Text]

				S. Patel, S. Freedman, K. L. Chapman, F. Emms, A. E. Fletcher, M. Knowles, R. Marwood, G. Mcallister, J. Myers, S. Patel, et al. Biological Profile of L-745,870, a Selective Antagonist with High Affinity for the Dopamine D4 Receptor J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 636 - 647. [Abstract] [Full Text]